Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Chimeric antigen receptor T cells (CAR-T) targeting CD19 or B cell maturation antigen (BCMA) are highly effective against B cell malignancies. However, application of CAR-T to less differentially expressed targets remains a challenge due to lack of tumor-specific antigens and CAR-T controllability....

Full description

Bibliographic Details
Main Authors: Simon Loff, Josephine Dietrich, Jan-Erik Meyer, Julia Riewaldt, Johannes Spehr, Malte von Bonin, Cordula Gründer, Mridula Swayampakula, Kristin Franke, Anja Feldmann, Michael Bachmann, Gerhard Ehninger, Armin Ehninger, Marc Cartellieri
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
UniCAR
AML
ALL
CD123
CAR-T
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520300590

Internet

http://www.sciencedirect.com/science/article/pii/S2372770520300590

Similar Items